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Abstract Since the discovery of FOXN1 deficiency, the hu-
man counterpart of the nude mouse, a growing body of evi-
dence investigating the role of FOXN1 in thymus and skin,
has been published. FOXN1 has emerged as fundamental for
thymus development, function, and homeostasis, representing
the master regulator of thymic epithelial and T cell develop-
ment. In the skin, it also plays a pivotal role in keratinocytes
and hair follicle cell differentiation, although the underlying
molecular mechanisms still remain to be fully elucidated. The
nude severe combined immunodeficiency phenotype is in-
deed characterized by the clinical hallmarks of athymia with
severe T cell immunodeficiency, congenital alopecia, and nail
dystrophy. In this review, we summarize recent discoveries in
the field and give interesting perspective about new and prom-
ising therapeutic approaches for disorders of immune system
with athymia.
Keywords FOXN1 . Severe combined immunodeficiency .
Athymia . Nude SCID phenotype . Nudemouse . Tcell
development . Thymus transplantation
Introduction
Severe combined immunodeficiency (SCID) indicates a clin-
ically and genetically heterogeneous group of congenital dis-
orders due to abnormalities of development and/or function of
T, B, and NK cells, always resulting in impairment of both
cellular and humoral immunity. To date, more than 20 genetic
alterations have been identified as responsible for the disease
[1]. Among these, the FOXN1 gene mutation, causative of the
nude SCID phenotype, is the unique condition in which the
immunological defect is related to an alteration of the thymic
epithelial stroma and not to an intrinsic defect of the hemato-
poietic cell. The nude SCID phenotype has been identified in
human for the first time in 1996 in two female patients who
presented with thymus aplasia and ectodermal abnormalities
[2], approximately 30 years later than the initial description of
the murine counterpart. Thereafter, several nude SCID pa-
tients from all over the world have been described in the lit-
erature [3–5]. The immunological phenotype is T−/lowB+NK+,
with a profound functional T cell impairment, leading to se-
vere and life-threatening infections in the first months of life.
In addition to the classical SCID phenotype, the patients af-
fected also exhibited extra-immunological features, involving
primarily the skin and hair.
FOXN1 is a member of the forkhead box gene family that
comprises a diverse group of Bwinged helix^ transcription
factors implicated in a variety of cellular processes: develop-
ment, metabolism, cancer, and aging [6]. While during fetal
life FOXN1 is expressed in several mesenchymal and epithe-
lial cells, including those of the liver, lung, intestine, kidney,
and urinary tract, its postnatal expression is restricted to stro-
mal thymus and skin cells, where FOXN1 is necessarily re-
quired for the normal development, function, andmaintenance
of hair follicles and thymic epithelial cells (TECs). However,
the molecular mechanisms by which FOXN1 expression and
activity are regulated are only incompletely understood.
The aim of this review is to give an updated and broad
picture of the role of FOXN1, and its implications in hu-
man disease, based on previously published work, which
we hope may be proven useful for both clinicians and sci-
entists in the field. We will begin by summarizing the
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history of FOXN1 discovery in mice and humans, dissect-
ing the human nude SCID phenotype and the disease
mechanisms through the elucidation of the role of
FOXN1 in the thymus, skin, and nervous system, followed
by treatment options and relative outcome of the disease
and potential future areas of research.
The Role of Foxn1 Revealed by Animal Models:
the Nude Mouse
The nude mouse phenotype has been described by
Flanagan in 1966, after its spontaneous appearance in the
Virus Laboratory of Ruchill Hospital, Glasgow, UK [7].
This mouse showed abnormalities of hair keratinization
and thymic dysgenesia, resulting in both hairlessness and
profound T cell immunodeficiency, indicating that the gene
exerted pleiotropic effects. Indeed, positional cloning
allowed to identify a member of the forkhead or winged
helix superfamily, Foxn1 (originally referred as winged
helix nude, Whn), as the gene mutated [8–10]. Mice homo-
zygous for the mutation Bnude,^ nu/nu mice, were hairless,
had delayed growth, decreased fertility, and died early in
life because of severe infections. In particular, as con-
cerned the skin, hair follicles were present in the same
number in wild-type control and nude mouse; however,
in the latter, these follicles result in a hair that started to
twist and coil due to the absence of free sulfhydryl groups
in the mid-follicle region, thus failing to penetrate into the
epidermis. In these mice, moreover, the differentiation of
the epidermis was abnormal as well, and characterized by
abnormal balance between proliferation and differentiation
of keratinocytes in the hair follicle [11, 12]. In addition to
these cutaneous abnormalities, the immunological hall-
mark of the nude mice was an abnormal, or even absent,
thymus, resulting in a severe T cell deficiency and an over-
all severely impaired immune system. The thymus mor-
phogenesis was blocked at the beginning of the develop-
ment, resulting in a profound alteration of the organ archi-
tecture with no subcapsular, cortical, and medullary region
formation [9]. In addition, the hair growth could not be
rescued by thymus restoration, indicating that the annexa
abnormality was due to a direct role of the gene in epider-
mis differentiation [9, 13]. In support of this, the nude
phenotype was also characterized by nail malformations
and severe infertility. The first condition was attributed to
an abnormal production of fillagrin, a protein of the nail
matrix and plate, subsequent to the loss of keratin 1 pro-
tein. Differently, the infertility, related to small ovaries
with low egg counts in the females and no motile sperm
in the males [7], may be the result of hormonal changes, as
demonstrated by the altered serum levels of estradiol, pro-
gesterone, and thyroxine [14].
FOXN1 Deficiency in Humans: the Nude SCID
History
Most of the knowledge on cell-mediated immunity and par-
ticularly on Tcell thymic lymphopoiesis originated from stud-
ies performed in the nude SCID mouse model. Since its first
description and the identification of FOXN1 gene, more than
100 papers have been published dissecting its immunological
role. As for the human phenotype, for many years, DiGeorge
syndrome has been erroneously considered the human coun-
terpart based on the thymic aplasia or hypoplasia [15].
However, DiGeorge syndrome shows a wide spectrum of clin-
ical features, including parathyroid and cardiac and great ves-
sel malformations [16, 17], absent in the nude phenotype,
whereas the hallmarks of the nude SCID, hairlessness and
abnormalities of skin annexa, are missing. More importantly,
the immune defect in DiGeorge patients is also much less
severe than the nude phenotype [17]. The identification of
the full equivalent human phenotype of nude mouse occurred
surprisingly about 30 years later with the description of two
Italian sisters, who presented congenital alopecia, eyebrows,
eyelashes, and nail dystrophy associated with a severe T cell
immunodeficiency, as detailed below [2]. The consanguinity
of the parents and the small community where the patients
originated from suggested an autosomal recessive inheritance
[18]. The time gap from the original mouse description led to
hypothesize a lethal phenotype in subjects with complete
expression.
Genetics
FOXN1 gene is located on chromosome 17q11.2 and consists
of eight exons, spanning about 30 kb [19] (Fig. 1). Interesting,
two different first exons, which are noncoding, have been
identified through an extensive screening of cDNA clones
obtained from skin cells, the exons 1a and 1b, that undergo
to alternative splicing [20]. This suggests the presence of two
distinct promoters of exons 1a and 1b [21]. The alternative
usage of the exon 1a or 1b seems to be tissue specific, in that
promoter 1a is active in thymus and skin, while promoter 1b is
active only in skin [20].
Up to date, only three mutations of the FOXN1 gene have
been reported in humans: the R255X, the S188fs, and the
R320W [2–5]. These mutations are located in different do-
mains of the molecule, and all resulted in a loss of function
of the protein (Fig. 1). The first mutation identified, the
R255X, resulted from a homozygous 792C-T aminoacidic
transition in the N-terminus exon 5, leading to a premature
stop codon causing the truncation of the protein before the
start of the evolutionary conserved forkhead domain. The
R320W was a homozygous missense mutation located in the
forkhead domain (exon 6) in which aminoacidic substitution,
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C987T, impaired its DNA binding ability, and thus the tran-
scriptional regulation of target genes. The last reported S188fs
mutation was a small deletion of exon 2, c.562delA, also
resulted in a frameshift and premature truncation of the protein
after the first 24 amino acids of the forkhead domain.
Focus on Immunodeficiency: FOXN1 in TECs and T
Cell Development
All nude SCID patients reported so far showed decreased T
cell counts [2–5], with a predominant reduction of CD4+ T
cells [2, 3] and an increase of double-negative lymphocytes in
the peripheral blood [3, 4]. T cells had a poor or absent pro-
liferative response to mitogens and exhibited an oligoclonal
TCR repertoire [2–4]. NK and B cells, although normal in
number, were also functionally impaired with abnormal spe-
cific antibody production [2–5]. The T cell immunodeficiency
resulted also in a severe reduction of T cell receptor rearrange-
ment excision circles (TRECs) [3], CD31+ recent thymic em-
igrants [4], and naïve CD4+ CD45RA+ T cells, the latter turn-
ing in favor of a CD45RO+ memory phenotype [3, 4, 22].
The identification of the nude/SCID phenotype greatly
contributed to unravel important issues of thymic and T cell
development. Studies on both mouse and human have dem-
onstrated that the transcription factor FOXN1 plays a key role
in the morphogenesis of the three-dimensional thymic archi-
tecture, which is important for the functionality of the thymus.
In particular, Foxn1 is expressed in all TECs during initial
thymus organogenesis and is required to induce both cortical
andmedullary thymic epithelial cell differentiation [9, 23–26].
Moreover, FOXN1 is considered essential also for the preven-
tion of thymic involution during adulthood [27–29]. In partic-
ular, in mice, Foxn1 mainly regulates TEC differentiation and
homeostasis during fetal and postnatal life [28, 30]. TECs are
implicated in either thymus organogenesis or most stages of
the maturation of T cell precursors [31, 32] (Fig. 2). In a
Foxn1-dependent manner, TECs release several chemokines,
including CCL25, CCL21, and CXCL12, that allow hemato-
poietic progenitors to enter into the developing thymus [33,
34]. These progenitors, subsequently, are committed to a Tcell
fate and progress through the different phases of the
ontogenesis, thanks to the crosstalk with TECs and under
the stimuli of TEC-derived molecules, such as the notch li-
gand DLL4, which, in turn, is also transcriptionally regulated
by FOXN1 [35, 36]. In developing T cells, cortical and med-
ullary TECs (cTECs and mTECs) induce the Bpositive^ and
Bnegative^ selection processes, respectively, with mTECs act-
ing only in negative selection [37] (Fig. 2). These processes
are driven by MHC–self-antigen complexes presented on the
surface of TECs [38, 39] (Fig. 2). In addition to CCL25,
CXCL12, and DLL4, FOXN1 has been recently proven to
promote the expression of hundreds of genes in TECs that
support intrathymic T cell development through the antigen
processing and presentation. In particular, it was found that the
expression of Prss16 in cTECs, which encodes a thymus-
specific serine protease required for CD4 lineage selection
and high MHCII expression, is regulated by Foxn1 [34].
Moreover, a direct binding target of Foxn1 has been detected
uniquely in cTECs, represented by a cis-regulatory element
involved in the transcriptional promotion of relevant cTEC
genes. Indeed, the Foxn1 binding to this element promotes
the transcription of β5t gene, the catalytic subunit of cTEC
thymoproteasome, which has an essential role in positive se-
lection induction of functionally competent CD8+ T cells
within the thymus [40]. In the absence of FOXN1 expression
in TECs, the thymic development is thereby blocked at a
rudimentary stage [27, 28, 34], characterized by an alymphoid
two-dimensional anlage with a cystic structure [22, 41, 42]. In
this thymic rudiment, TECs are not capable to allow the he-
matopoietic precursor cells (HPCs) to enter into the epithelial
cluster [43]. Taken together, this evidence strongly demon-
strated the pivotal role of the lymphostromal crosstalk.
Nevertheless, significant numbers of circulating T cells of
non-ma te rna l o r ig in wi th major expans ions o f
CD3+CD4−CD8−αβTCR have been documented in all cases
reported of homozygous R255X FOXN1 deficiency [2, 3].
Differently, no circulating T cells were found in the patient
with the R320W mutation [3]. A possible explanation is that
a thymic rudiment may persist, supporting a limited produc-
tion of T cells. An alternative explanation is that an extra-
thymic site of T cell differentiation is capable to support the
development, albeit with a narrow TCR repertoire and im-
paired T cell selection. Furthermore, during prenatal T cell
Fig. 1 Schematic representation
of the FOXN1 gene with the
distinct eight exons and protein
domains showing the position of
identified mutations annotated by
amino acid alterations
J Clin Immunol
development in humans, it has been observed that FOXN1
mutation completely abrogates T cell ontogeny of CD4 com-
partment, while having a limited production of CD8+ cells,
indicating a possible different origin of these cells [42].
Focus on Ectodermal Abnormalities: FOXN1
and the Skin
In addition to athymia and T cell immunodeficiency, FOXN1
mutations are also associated with ectodermal defects of skin
and hair, namely alopecia of the scalp, eyebrows, and eye-
lashes and nail dystrophy. In both patients and nude mice, hair
follicles are normal in number but give rise to altered hairs
unable to curl and that break off at the level of the skin surface
leading to alopecia [7, 44]. As for nail dystrophy, the most
frequent features were leukonychia and koilonychia (Bspoon
nail^), the first one characterized by a proximal arciform al-
teration of the nail plate and the second one by a concave
surface and raised edges of the distal nail plate [45].
Canaliform dystrophy and transverse groove of the nail plate
(Beau line) were also noted, although less frequently. The
same skin annexa alterations were also reported in a few
strains of nude mice [12].
Studies from mouse skin revealed a specific pattern of ex-
pression of Foxn1 in both epidermis and hair follicle, indica-
tive of its involvement in cell growth and differentiation pro-
cesses, and particularly of its role as regulator of starting ter-
minal differentiation [21]. Indeed, in the epidermis, Foxn1 is
primarily expressed in the keratinocytes of the first suprabasal
layer, which stopped to proliferate and initiated terminal dif-
ferentiation [12], although rare cell Foxn1+Ki67+ was found
in the basal layer, likely representative of the very early stages
of commitment to differentiation [46]. Similarly, in the hair
follicle, Foxn1 expression was found in cells located in the
supramatrical region and ready to begin terminal differentia-
tion [47, 48]. Functionally, although molecular pathways still
remain to be fully elucidated, Foxn1 promotes keratinocyte
differentiation through the regulation of more than 50 target
genes, including protein kinase B and protein kinase C (PKC),
the latter being a potent inhibitor of human hair follicle growth
in vitro [49–51]. In keeping with this, PKC activity was found
upregulated in Foxn1−/− mouse keratinocytes, while Foxn1
overexpression determined the suppression of PKC activation
Fig. 2 Intrathymic T cell development. Lymphoid progenitor cells get
access into the thymus through the vessel of the corticomedullary junction
under the stimuli of Foxn1-related chemokines released by cTECs.
Double-negative (DN) lymphocyte (CD4− CD8−) interaction with
cTECs in the thymic cortex allows them to maturate through different
double-negative stages and finally generate double-positive (DP) lym-
phocytes (CD3+CD4+CD8+). cTECs, expressing specific genes under
the control of Foxn1, are involved in positive selection. In the medulla,
positively selected lymphocytes interact with mTECs to complete the
maturation process. Self-reactive lymphocytes are further deleted,
through the so-called negative selection. Eventually, single-positive
(SP) (CD3+CD4+ or CD3+CD8+) lymphocytes are generated and released
in the peripheral blood
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and inhibition of keratinocyte differentiation [51]. Studies per-
formed on human epidermal keratinocytes confirmed the role
of FOXN1 in the initiation of keratinocyte differentiation, but
it was found to be not sufficient to induce the final stages of
terminal differentiation [52].
Focus on Neurological Abnormalities: FOXN1
and the Nervous System
Up to date, central nervous system (CNS) abnormalities have
only been found in two fetuses carrying the R255X mutation
from the same family in the highly consanguineous village of
Acerno [53, 54]. The first fetus showed severe neural tube
defects, such as anencephaly and spina bifida, while the sec-
ond one had milder defects including an enlarged interhemi-
spheric fissure with the absence of the cavum septi pellucidi
and corpus callosum [53, 54]. Although other members of the
forkhead/winged helix family proteins, such as mouse HNF-
3b and BF-1 and human FOXP2, were reported to be involved
in CNS development and function [55, 56], the absence of
neurological abnormalities in nude mouse models along with
the high rate of consanguinity in the population of the two
fetuses suggested that another genetic etiology could have
caused the neurological features. Thus, the role of FOXN1
in CNS development still remains unconfirmed and to be fur-
ther investigated [53].
FOXN1 Mutations in Heterozygous Subjects
In the small community of south Italy, where the first two
sisters with FOXN1 deficiency where identified, additional
cases of patients with congenital alopecia and early child death
because of severe infections were reported [18]. Interestingly,
55 subjects of 843 inhabitants studied were found to carry the
heterozygous FOXN1 mutation. All the carriers and affected
cases identified belonged to an extended seven generational
pedigree, derived by a single ancestral couple born at the
beginning of the nineteenth century from which four family
groups originated. Physical examination of the identified het-
erozygous subjects revealed that 39 of the 55 heterozygous
subjects showed a nail dystrophy. Leukonychia, characterized
by a typical arcifom pattern reminiscent of a half-moon and
involving the proximal part of the nail plate, was the most
specific phenotypic alteration together with koilonychia and
Beau line. Immunological alterations have also been docu-
mented in a heterozygous carrier, including lymphopenia
and absence of TREC (personal communication by Dr.
Gelfand). Unfortunately, no lymphocyte counts or other lab
investigations were performed in the large group of heterozy-
gous subjects of south Italy [18].
Focus on Therapy and Long-Term Outcome: HSCT
and Thymus Transplantation
The SCID diagnosis requires a prompt and appropriate
treatment, that in the majority of cases is represented by
hematopoietic stem cell transplantation (HSCT) that leads
to reconstitute the immune system before the onset of life-
threatening complications. The sooner the HSCT is per-
formed, the better the outcome [57]. As for nude SCID,
since thymic stromal alterations due to FOXN1 mutation
underlie the immune defect, thymus transplantation could
be a good alternative therapeutic approach to HSCT, even
though conclusive results are still not available. Restoring
a functional thymic stromal environment is expected to
provide a long-lasting immune reconstitution [3, 4]. In
complete DiGeorge syndrome, it has been observed that
HSCT did not result in a high-quality immune reconstitu-
tion [22, 58–61].
Of the nine nude SCID patients reported, five of them
have been treated in order to achieve immune reconstitu-
tion, three receiving HLA-matched sibling/genoidentical
HSCT at 5 months of age [2, 4, 5, 22] and two with
thymus transplantation at the age of 9 and 14 months
[3]. One of the HSCT recipients 6 years after HSCT
was alive and infection-free with reconstitution of
CD3+, CD4+, and CD8+ subsets, although naïve CD4+
lymphocyte regeneration and lymphocyte proliferative ca-
pacities were impaired [22]. Surprisingly, naïve CD8+ cell
was normal, suggesting a different thymus requirement
for the generation of naïve CD4+ or CD8+ lymphocytes.
The other HSCT recipients died due to post-transplant
complications [4, 5]. In the other two cases treated with
thymus transplantation, a successful T cell lymphopoiesis
was restored with the development of a functional T cell
compartment, although it took several months. Both pa-
tients showed a normal T cell number, TREC-positive
naïve CD4+ T cells, and CD31+ recent thymic emigrants
in the peripheral blood. Moreover, the newly generated T
cells showed normal proliferative response in vitro, de-
veloped a diverse TCR repertoire, and were able to sup-
port B cell function, leading to normalization of Ig levels
and production of specific antibodies directed against T
cell-dependent antigens [3, 62]. The functional immune
reconstitution allowed both patients to clear the ongoing
pre-transplantation infections and to remain infection-free
at 3 and 5 years after thymic transplant, although one
patient developed autoimmune hypothyroidism and vitili-
go [3, 63].
In conclusion, although thymic transplantationmay be con-
sidered a promising therapeutic option in nude SCID patients,
it should be considered as the most appropriate treatment only
if a HLA-matched sibling donor is not available and when a
rapid T cell recovery is not needed.
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Future Perspective: Surrogate Organ
Recent evidence documented a new promising perspective,
consisting of a scaffold mimicking the three-dimensional ar-
chitecture of thymus, whichmay be potentially useful to allow
the differentiation of hematopoietic cell precursors and, even-
tually, the restoration of functional immune system in congen-
ital immunodeficiencies with athymia, such as nude SCID and
DiGeorge syndrome. In keeping with this, Clark et al. docu-
mented that human skin fibroblasts and keratinocytes arrayed
on a synthetic three-dimensional matrix were capable to sup-
port the development of functional human T cells from hema-
topoietic precursor cells in the absence of thymic tissue [64].
The newly generated Tcells exhibited the same characteristics
of recent thymic emigrants, contained T cell receptor excision
circles, possessed a diverse T cell repertoire, and were func-
tionally mature and tolerant to selfMHC, indicating a success-
ful differentiation process [64]. Thereafter, using a poly ɛ-
caprolactone (PCL) scaffold reconfiguring a three-
dimensional microenvironment, it has been shown that in
the absence of thymic cellular epithelial elements, it is possi-
ble in succeeding the commitment of lymphoid precursors to
the T cell lineage [65–67]. In particular, it has been document-
ed a de novo generation in the matrix of cells of the T lineage
expressing surface and molecular markers of early Tcell com-
mitment. In particular, a downregulation of TAL1 and upreg-
ulation of Spi-B genes, consistently with the loss of the
multilineage differentiative potential, was found [65].
Furthermore, PTCRA and RAG2 expressions were also detect-
able during the culture, indicating that a recombination activ-
ity, indispensable for the generation of a T cell repertoire, was
active [65]. However, a full maturation process in the matrix
was not achieved, suggesting that additional factors or molec-
ular manipulations could be necessary to create a TEC-like
surrogate microenvironment capable to support the entire pro-
cess of T cell ontogenesis. Nevertheless, effort should be max-
imized in this field of research, since the in vitro re-build of
such a surrogate organ capable of reproducing tissue features
of primary lymphoid organs is a promising helpful tool for
future therapeutic strategies in patients affected with congen-
ital disorders of immune system related to athymia.
Conclusion
Nude SCID due to FOXN1 mutations is a rare form of immu-
nodeficiency with only a few cases documented up to now,
characterized by severe T cell lymphopenia, alopecia, and nail
dystrophy. Notably, the nude SCID phenotype is the only
form of SCID associated with an alteration of a gene that is
not expressed in the hematopoietic cell, but rather related to a
peculiar alteration of thymus anlage. This makes the disorder a
unique model of disease to investigate molecular pathways
involved in thymus dependent and independent T cell ontog-
eny. However, despite the increasing evidence, the detailed
mechanisms of FOXN1 action in thymus and skin still remain
to be fully clarified. Additional research in this field would be
very helpful in conclusively defining the role of FOXN1 in the
biological process and to pave the way for the development of
novel therapeutic strategies, such as thymic transplantation or
the generation of surrogate organ to treat congenital disorders
of immune system.
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